Pfizer Inc. announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5, 2018. Data from programmes in small molecules, immunotherapies, biomarker-driven medicines, as well as biosimilars, will be featured in more than 40 abstracts, including company-sponsored and collaborative research studies.

“The breadth and depth of our data at ASCO this year are indicative of our focus on understanding the full potential of our medicines, including Ibrance and Xtandi, which are already making a difference in patient lives. We are also exploring new and exciting pathways designed to transform treatment outcomes,” said Charles Hugh-Jones, MD, FRCP, chief medical officer, Pfizer Oncology. “Our comprehensive research is resulting in near-term potential benefits for patients, as well as multiple new therapies that we hope to introduce this year.”

The research to be presented includes new insights on Pfizer’s late-phase investigational compounds dacomitinib, lorlatinib, talazoparib and glasdegib, as well as Pfizer’s marketed therapy Xtandi (enzalutamide). These compounds represent the next five potential Pfizer Oncology advancements in lung, breast, hematologic and prostate cancers.

“At this year’s ASCO, we’re particularly excited to present overall survival data for dacomitinib that builds upon our precision medicine focus and legacy in lung cancer,” said Mace Rothenberg, MD, chief development officer, Oncology, Pfizer Global Product Development. “Further, we’ll be sharing new insights on our medicines across 16 disease areas and 13 mechanisms of action, including early-phase through post-approval analyses. Our extensive presence reinforces our commitment to speeding accessible breakthrough medicines to patients.”

The first presentation of final overall survival results from the pivotal ARCHER 1050 study of dacomitinib vs. gefitinib in locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutation

Phase 2 results from a clinical research collaboration evaluating Ibrance (palbociclib) in combination with cetuximab in platinum-resistant HPV unrelated recurrent/metastatic head and neck squamous cell carcinoma

An analysis of resistance to therapy based on genetic mutations from the pivotal PALOMA-3 trial of CDK 4/6 inhibitor IBRANCE in combination with fulvestrant in ER+/HER2- metastatic breast cancer

Longer-term efficacy and safety results from two registrational trials: the JAVELIN Merkel 200 study of PD-L1 inhibitor Bavencio (avelumab) in a rare skin cancer, being developed in collaboration with Merck KGaA, Darmstadt, Germany and the BFORE trial of Bosulif (bosutinib) vs. imatinib in patients with newly diagnosed chronic myeloid leukemia A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.